HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $15 to $7.
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $15 to $7.